GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the ...

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...

GSK has announced a 50/50 joint venture with leading Indian vaccines company, Biological E, for the early stage research and development of a six-in-one combination paediatric vaccine to help ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and ...

GSK Plc shares rose on Wednesday, buoyed by a US court’s decision to review whether evidence supporting claims that heartburn drug Zantac causes cancer is scientifically sound. The British ...

The Department of Chemical and Biological Engineering at Northwestern University is pioneering transformational discoveries in synthetic biology, biotechnology, catalysis, medicine, complex systems, ...

Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints Vaccine candidate based on CureVac's ...

GSK Plc’s RSV vaccine has been approved for wider use in adults in Europe in a boost for the UK company’s blockbuster shot. The European Commission recommended GSK’s Arexvy for adults aged ...

GSK (NYSE:GSK) stock was up 3% in afternoon trading Tuesday in the wake of a ruling by a Delaware court on whether certain evidence should be allowed in an ongoing case over the safety of its ...

Nigeria’s pharmaceutical sector has seen high import duties and other barriers weigh heavily on their operations, as they ...

Given the large stake in the stock by institutions, GSK's stock price might be vulnerable to their trading decisions 51% of the business is held by the top 25 shareholders Insiders have been ...